For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of this treatment and Tafamidis meglumine represents a significant advancement . These novel therapies preserve the transthyretin protein, halting its damaging build-up and lessen